Israel's Largest Venture Capital Firm to Focus on Health Care
Named aMoon2 and led by Marius Nacht and Dr. Yair Schindel, the company has $660 million to invest
Teva Pharmaceutical
Opioid Suits Against Sackler Family's Purdue May Cost Teva Up to $3 Billion
Purdue Pharma said to be exploring bankruptcy filing as litigation pressures mount
Business in Brief: Drone Maker Aeronautics Signs Deal to Be Sold to Rafael, Avihai Stolero
Housing & Construction reaches agreement to buy American builder ■ Teva reaches settlement with U.S. on ‘pay-for-delay’ drug deals ■ Delek in advanced talks to sell Phoenix to U.S. fund Centerbridge ■ Bezeq and B Comm pace gains for Tel Aviv shares
Teva CEO: Company Would Have Gone Bankrupt Without Layoffs
After having to layoff 1,350 workers in Israel, Kare Schultz describes crisis of the pharmaceutical company which suffered from dropping generic sales in the U.S. market
Business in Brief: TASE CEO Says Government Is Undercutting Capital Markets
Tel Aviv shares mark their fifth rise in last six sessions ■ Buffet’s Berkshire Hathaway sees Teva holding lose $264 million in value ■ Ratio Petroleum soars on start of Guyana oil exploration ■ Plus500 admits to typo that misled investors about losses
Business in Brief: Bezeq to Petition Court on Merging Units
Plantext to be first Israeli cannabis company to be traded overseas ■ Stanley Fischer hired to advise BlackRock ■ Wall Street weighs down Tel Aviv shares
Business in Brief: Super Pharm Gearing Up for Tel Aviv Stock Exchange IPO
Tel Aviv shares end higher, despite Teva Pharmaceuticals selloff ■ Bondholders backing alternative to Africa Properties
Teva Shares Take Tumble After Warning of Bleak 2019
Israeli drug maker sees a repeat this year of the tough market conditions of 2018
Teva Selling Northern Israeli Plant to FIMI Fund for $45 Million
The sale of the Kiryat Shmona facility was made possible by a collective labor agreement between Teva and the 170 plant workers
Business in Brief: Tel Aviv Shares Eke Out Gains as Energy Shares Rally
Teva migraine drug fails to win coverage by major pharma benefit manager ■ S&P affirms Israel’s credit rating despite fiscal setbacks
Teva’s Generic EpiPen U.S. Launch Still Stalled Five Months After Approval
Short supply is missed opportunity for Israeli drug maker in $750 million market
Major U.S. Drugstore CVS to Cover Migraine Drugs From Teva
CVS Health Corp has decided to add migraine drugs from Teva and Eli Lily and Co to its list of covered drugs, excluding Amgen Inc whose shares have recently fallen
Business in Brief: Pharma Shares Take Tel Aviv Stock Exchange Higher
Shari Arison sells Israeli salt monopoly to Fortissimo fund ■ Five companies weighing bids to set up small-business lender
Business in Brief: Tel Aviv Shares Post Fourth Straight Rise
Teva CEO Schultz says company’s key U.S. generics market has stabilized ■ Naphtha to make tender offer for Isramco ■ Current, former Aeronautics executives suspected of insider trading
Business in Brief: Teva Threatened With Strike at Main Plant for Making Top-selling Copaxone Drug
Two reach plea deal in fraud case ■ Brookland’s controlling shareholder quits ■ Radware buys Indian company ■ stocks extend gains
Business in Brief: Tel Aviv Shares Quietly Mark End of Stormy Year
Teva said to be in talks to sell Oncotest diagnostics unit ■ Africa Israel bailout collapses as Moti Ben-Moshe asks for deposit back
Business in Brief: Dollar at Two-year High Versus Shekel
Teva shareholders demand company sue U.S. employees over role in alleged cartel ■ Tel Aviv shares ride back of Wall Street rebound as China trade fears ease
Teva Suspected of Being Part of a Cartel in U.S. Engaged in Price-fixing and Dividing Market for Generics
The Israeli generics manufacturer is one of 16 drug firms under investigation over purported price-fixing involving 300 medications
Business in Brief: Teva Patent Dispute With Swiss Firm Reaches U.S. Supreme Court
Warburg Pincus in talks with Allied Holding to sell it Leumi Card stake ■ Corning reportedly in talks to buy Israel’s Teldor Cables ■ Taptica shares plunge after CEO quits following fraud ruling ■ Tel Aviv shares fall as optimism on U.S.-China trade ebbs
Teva Shares Rally, Forecast 'Very Strong Launch' for Long-awaited Ajovy Migraine Treatment
The company added that it expected to launch its generic version of the best-selling EpiPen allergy treatment in the current quarter
Business in Brief: Teva Leads Sharp Rise in Tel Aviv Shares
Little-known Krausz Metal Industries fetches $135 million from U.S. buyer ■ Boards approve merger of JOEL into parent company Equital ■ Israel Chemicals profit rose 16.5% in quarter
Teva Raises 2018 Earnings Outlook, Says 'Very Good Signs' of New Drug Launch
Teva has been counting on its long-awaited migraine drug to revive its fortunes after suffering a drop in revenue
Teva Loses Negotiations Over New Migraine Drug, Stock Falls 5 Percent
The Israeli pharmaceutical company's new drug will not be covered by U.S. prescription benefits manager, though it's competitors will.
Lilly Defeats Teva Patent Lawsuits Over Migraine Drug
Teva was trying to block its competitor from bringing its migraine drug Emgality to market in the United States
Business in Brief: Foamix Soars on Trials for Acne Treatment
Opko chief, ex-Teva chairman Phillip Frost charged with share manipulation in U.S. ■ Generation Capital takes 50% stake in power plant operator Rapac Energy ■ TASE ends lower after long holiday weekend
Business in Brief: Israeli Government Gained $275 Million by Delaying Leumi Share Sale
Teva offers to buy back $400 million in bonds ■ RADA cashes in on drone-threat fears ■ TASE closes in the red, dragged down by Wall Street
FDA Approves Teva's Generic Version of Mylan's EpiPen
Teva Pharmaceutical's version of Mylan NV's EpiPen to provide 'lower-cost option' for patients 'living with severe allergies,' FDA commissioner says
Warren Buffett Buys $60 Million Worth of Teva in the Dip
Berkshire Hathaway also massively invested more in Goldman Sachs and Apple
Teva Shares Tumble After Company Disappoints Markets
The pharmaceutical company is in a $28.4 billion debt. Analysts says the company still lacks growth drivers
Teva Surprises With Better-than-expected First Quarter
Trouble drugmaker offers rosier outlook for rest of year, despite delay in approval for key migraine treatment